Medco Research's Adenocard (adenosine)
Executive Summary
Medco Research's Adenocard (adenosine): Has received "approvable" status from FDA, the company announced Oct. 26, adding that it hopes to receive final approval in November. The injectable anti-arrhythmic product would be approved for I.V. treatment of paroxysmal supraventricular tachycardia in a hospital setting. Medco has licensed the drug to Fujisawa (Lyphomed) for marketing in the U.S. and to Sanofi for marketing outside North America. The drug was recommended for approval by FDA's Cardio-Renal Drugs Advisory Committee on May 4 ("The Pink Sheet" May 8, p. 7). The company is developing the drug for at least seven other indications.